Antibody Drug Conjugate News and Research

RSS
PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

Pfizer to present data on ADCs at AACR 2012

Pfizer to present data on ADCs at AACR 2012

UC Cancer Institute to enroll up to 60 patients for AMG 595 phase-1 trial

UC Cancer Institute to enroll up to 60 patients for AMG 595 phase-1 trial

Diffusion-weighted MRI may effectively indicate response to ovarian cancer treatment

Diffusion-weighted MRI may effectively indicate response to ovarian cancer treatment

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Exposure to goats could increase risk of pneumonic-type lung adenocarcinoma

Exposure to goats could increase risk of pneumonic-type lung adenocarcinoma

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

NIA awards UK Sanders-Brown Center on Aging ADC to continue Alzheimer's research

NIA awards UK Sanders-Brown Center on Aging ADC to continue Alzheimer's research

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Australian TGA approves GI Dynamics EndoBarrier Gastrointestinal Liner for type 2 diabetes and obesity

Australian TGA approves GI Dynamics EndoBarrier Gastrointestinal Liner for type 2 diabetes and obesity

FDA ODAC recommends approval of Seattle Genetics' ADCETRIS for Hodgkin lymphoma after ASCT

FDA ODAC recommends approval of Seattle Genetics' ADCETRIS for Hodgkin lymphoma after ASCT

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

EMA acceptance of brentuximab vedotin MAA triggers $5M milestone payment to Seattle Genetics

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Waters introduces SYNAPT G2-S at 59th ASMS Conference on Mass Spectrometry

Waters introduces SYNAPT G2-S at 59th ASMS Conference on Mass Spectrometry

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.